Drug

C_max (ng/mL) CV%

T_max (h) CV%

t ½ (h) CV%

AUC_0-72h (ng·hr/mL) CV%

Baseline-corrected estrone

4.43 (40.4)

7.7 (30.3)

10.6 (25.4)

69.89 (39.2)

Equilin

3.27 (43.5)

5.8 (31.1)

9.7 (23.0)

46.46 (47.5)

The distribution of exogenous estrogens is similar to that of endogenous estrogens. Estrogens are widely distributed in the body and are generally found in higher concentrations in the sex hormone target organs. Estrogens circulate in the blood largely bound to sex hormone binding globulin (SHBG) and albumin.

Exogenous estrogens are metabolized in the same manner as endogenous estrogens. Circulating estrogens exist in a dynamic equilibrium of metabolic interconversions. These transformations take place mainly in the liver. Estradiol is converted reversibly to estrone, and both can be converted to estriol, which is the major urinary metabolite. Estrogens also undergo enterohepatic recirculation via sulfate and glucuronide conjugation in the liver, biliary secretion of conjugates into the intestine, and hydrolysis in the gut followed by reabsorption. In postmenopausal women a significant portion of the circulating estrogens exist as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active estrogens.

Estradiol, estrone, and estriol are excreted in the urine along with glucuronide and sulfate conjugates.

Cenestin was investigated in postmenopausal women. No pharmacokinetic studies were conducted in special populations, including patients with renal or hepatic impairment.

In vitro and in vivo studies have shown that estrogens are metabolized partially by cytochrome P450 3A4 (CYP3A4). Therefore, inducers and inhibitors of CYP3A4 may affect estrogen drug metabolism. Inducers of CYP3A4 such as St. Johns Wort preparations (Hypericum perforatum), phenobarbital, carbamazepine, and rifampin may reduce plasma concentrations of estrogens, possibly resulting in a decrease in therapeutic effects and/or changes in the uterine bleeding profile. Inhibitors of CYP3A4 such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice may increase plasma concentrations of estrogens and may result in side effects.

A randomized, placebo-controlled multicenter clinical study was conducted evaluating the effectiveness of Cenestin for the treatment of moderate to severe vasomotor symptoms in 120 postmenopausal women between 38 and 66 years of age (68% were Caucasian). Patients were randomized to receive either placebo or 0.625 mg Cenestin daily for 12 weeks. Dose titration was allowed after one week of treatment. The starting dose was either doubled (2 x 0.625 mg Cenestin or placebo taken daily) or reduced (0.3 mg Cenestin or placebo taken daily), if necessary. Efficacy was assessed at 4 and 12 weeks of treatment. By week 12, 10% of the study participants remained on a single 0.625 mg Cenestin tablet daily while 77% required two (0.625 mg) tablets daily. The results in Table 2 indicate that compared to placebo, Cenestin produced a reduction in moderate to severe vasomotor symptoms at weeks 4 and 12. A second randomized, placebo-controlled multicenter clinical study was conducted evaluating the effectiveness of 0.45 mg Cenestin tablets, for the treatment of moderate to severe vasomotor symptoms in 104 menopausal women between 52 and 74 years of age (76% were Caucasian). Patients were randomized to receive either placebo or 0.45 mg Cenestin daily for 12 weeks. Efficacy was assessed at 4 and 12 weeks of treatment. The mean change in the number of moderate to severe hot flushes per week shown in Table 3 indicate that compared to placebo, 0.45 mg Cenestin produced a reduction in moderate to severe vasomotor symptoms at weeks 4 and 12. A corresponding reduction in the severity of hot flushes was demonstrated at weeks 5 and 12.

Table 2 Clinical Responsea Mean Change in the Number of Moderate to Severe Hot Flushes Per Week, 0.625 mg and 2 x 0.625 mg Cenestin, ITT Population

Brand Name: Cenestin Generic Name: Synthetic conjugated estrogens « Previous Clinical Pharmacology Next » Next: Cenestin - Patient Information » « Previous: Cenestin - Overdosage & Contraindications Bookmark this page: WebMD Resources How Safe Are Your Painkillers Hysterectomy Recovery: What To Expect Easily Distracted? Check Your Symptoms Menopause Myths A generation ago, no one talked about menopause. Today it's openly discussed. But some common menopause myths persist. See more WebMD Videos » Privacy Policy Women's Health Find out what women really need. Experiencing Menopausal Symptoms? Learn More About Menopause Assess Your Symptoms Take Action — Make a Plan Cenestin Drug Description Indications & Dosage Side Effects & Drug Interactions Warnings & Precautions Overdosage & Contraindications Clinical Pharmacology Patient Information Related Drugs Estratest Estring Menest Premarin Premarin Injection Prempro Health Resources Menopause Hormone Therapy Treatment for Hot Flashes Drug News 2008 Election & Health Care on WebMD. Get Informed. Schizophrenia Has a New Shot Treatment Kid Antipsychotics Might Lead to Weight Gain 'Abuse-Proof' OxyContin Nixed by FDA View More » Search the Medical Dictionary for Health Definitions & Medical Abbreviations Updated & New News & Features Identify Your Drugs: Use the RxList Pill Identification Tool Add RxList Search to Your Website Google Subscribed Links & RxList RxList Home|Drugs & Medications A-Z List |Pill Identification Tool |Drug Medical Dictionary |Diseases & Conditions About RxList|Contact RxList|Terms & Conditions|Privacy Policy|Sponsor Policy|Site Map WebMD®|MedScape®|eMedicineHealth®|MedicineNet® Copyright © 2008 by RxList Inc. RxList does not provide medical advice, diagnosis or treatment. See additional information.